CLINICAL TRIALS PROFILE FOR GLPG3667
✉ Email this page to a colleague
Clinical Trials for GLPG3667
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04097938 ↗ | A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 | Completed | Galapagos NV | Phase 1 | This study is a first-in-human, Phase I, randomized, double-blind, placebo-controlled, single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of GLPG3667 after oral single ascending doses (SAD) of GLPG3667 (part 1) and after oral multiple ascending doses (MAD) for 13 days of GLPG3667 (part 2) in healthy male subjects. In addition, the effect of food (FE) on safety, tolerability, and PK of GLPG3667 oral suspension will be evaluated (part 3 - will not be completed), and the relative bioavailability (rBA) of the capsule versus the oral suspension with the effect of food on the bioavailability of the capsule (part 4), both part 3 and 4 using an open-label, randomized, crossover design. |
| NCT04594928 ↗ | A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis | Completed | Galapagos NV | Phase 1 | The purpose of this research study is to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects with moderate to severe plaque psoriasis. |
| NCT04736927 ↗ | Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects | Completed | Galapagos NV | Phase 1 | A study in healthy volunteers to look at the effect of the test medicine, GLPG3667, on how midazolam (MDZ) is taken up and eliminated by the body. |
| NCT04976270 ↗ | A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects | Recruiting | Galapagos NV | Phase 1 | This study is a phase I, randomized, double-blind, placebo-controlled, single-center, to evaluate the safety, tolerability, and pharmacokinetics (PK) of GLPG3667 after an oral single dose (SD) of GLPG3667 (part 1) and after oral multiple doses (MD) for 13 days of GLPG3667 (part 2) in healthy male subjects. |
| NCT05272683 ↗ | Drug-drug Interaction Study With GLPG3667 and Itraconazole in Healthy Subjects | Not yet recruiting | Galapagos NV | Phase 1 | The main purpose of this study is to determine the effect of itraconazole on the amount of GLPG3667 that gets into the blood when the 2 drugs are administered together compared to when GLPG3667 is administered alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for GLPG3667
Condition Name
Clinical Trial Locations for GLPG3667
Trials by Country
Clinical Trial Progress for GLPG3667
Clinical Trial Phase
Clinical Trial Sponsors for GLPG3667
Sponsor Name
